Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

被引:0
|
作者
Masayuki Kanamori
Toshihiro Kumabe
Yukihiko Sonoda
Yoshikazu Nishino
Mika Watanabe
Teiji Tominaga
机构
[1] Tohoku University Graduate School of Medicine,Department of Neurosurgery
[2] Miyagi Cancer Center Research Institute,Division of Epidemiology
[3] Tohoku University Graduate School of Medicine,Department of Pathology
来源
Journal of Neuro-Oncology | 2009年 / 93卷
关键词
Oligodendroglioma; Dissemination; Predictive factors; Nestin; Ki-67;
D O I
暂无
中图分类号
学科分类号
摘要
The pattern of recurrence and predictive factors for tumor progression, dissemination and survival in oligodendroglial tumors were investigated. 56 consecutive patients with oligodendroglial tumors were retrospectively analyzed to determine the predictive significance of various factors, including World Health Organization grade, loss of chromosomes 1p and 19q, and immunohistochemical features of TP53, O6-methylguanine-deoxyribonucleic-acid-methyltransferase, CD44H, nestin, and Ki-67. Eleven patients developed dissemination, and had significantly shorter post-progression survival compared to ten patients with local recurrence. Univariate analysis showed that retention of chromosome 1p or 19q, Ki-67 labeling index ≥ 25%, diffuse expression of nestin, and p53 labeling index ≥ 10% were unfavorable factors for overall, progression-free, and dissemination-free survival. Multivariate analysis showed that Ki-67 labeling index ≥ 25% and diffuse expression of nestin were significant for dissemination-free survival. In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination.
引用
收藏
页码:219 / 228
页数:9
相关论文
共 50 条
  • [41] Overall and progression-free survival in metastatic basosquamous cancer: A case series
    Zhu, Gefei Alex
    Danial, Christina
    Liu, Andy
    Li, Shufeng
    Chang, Anne Lynn Su
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (06) : 1145 - 1146
  • [42] IMPACT OF EARLY LYMPHOCYTE RECOVERY ON PROGRESSION-FREE AND OVERALL SURVIVAL IN OSTEOSARCOMA
    Lee, Lynn
    Fei, Lin
    Pope, Jennifer
    Wagner, Lars
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 : S70 - S71
  • [43] Joint modeling of progression-free and overall survival and computation of correlation measures
    Meller, Matthias
    Beyersmann, Jan
    Rufibach, Kaspar
    [J]. STATISTICS IN MEDICINE, 2019, 38 (22) : 4270 - 4289
  • [44] Progression-free or overall survival...revisited in BOLERO-2
    Gupta, Sudeep
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2014, 35 (01) : 1 - 2
  • [45] Pre-operative hematological markers as predictive factors for overall survival and progression free survival in glioblastomas
    Marini, Alessandra
    Dobran, Mauro
    Aiudi, Denis
    Pesaresi, Alessandro
    di Somma, Lucia Giovanna Maria
    Iacoangeli, Maurizio
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2020, 197
  • [46] BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma
    Tabouret, E.
    Bequet, C.
    Denicolai, E.
    Barrie, M.
    Nanni, I.
    Metellus, P.
    Dufour, Henri
    Chinot, O.
    Figarella-Branger, D.
    [J]. EJSO, 2015, 41 (12): : 1685 - 1690
  • [47] PREDICTIVE MARKERS FOR OVERALL AND PROGRESSION-FREE SURVIVAL WITH CAPOX IN SECOND-LINE CHEMOTHERAPY OF METASTATIC COLORECTAL CANCER
    Solis Hernandez, M. D. P.
    Jimenez Fonseca, P.
    Perez, Q.
    Alvarez Fernandez, C.
    Ruiz, L.
    Rodriguez Rubi, D.
    Li, W.
    Sanchez, M. L.
    Faez, L.
    Vieitez, J. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 218 - 218
  • [48] A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model
    Stewart, David J.
    Bosse, Dominick
    Goss, Glenwood
    Hilton, John F.
    Jonker, Derek
    Fung-Kee-Fung, Michael
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
  • [49] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Belin, Lisa
    Tan, Aidan
    De Rycke, Yann
    Dechartres, Agnes
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (11) : 1707 - 1714
  • [50] IS PROGRESSION-FREE SURVIVAL A GOOD INDICATOR OF OVERALL SURVIVAL FOR PAZOPANIB IN PATIENTS WITH SYNOVIAL SARCOMA?
    Han, J.
    Lee, S.
    Cho, E.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S489 - S490